Suchergebnisse - "Soulières, Denis"

PubPharm (270)

1

Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma

enthalten in: Expert opinion on emerging drugs | 2024

von Proulx-Rocray, F. | Soulières, D.

2

Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC) : Results From the Canadian Kidney Cancer Information System (CKCis)

enthalten in: Clinical genitourinary cancer | 2024

von Graham, J. | Ghosh, S. | Breau, R. | +14

3

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454

enthalten in: European urology | 2024

von Plimack, E. | Powles, T. | Stus, V. | +18

ErratumFor: Eur Urol. 2023 Nov;84(5):449-454. - PMID 37500340

4

2023 European Society for Medical Oncology (ESMO) Congress Meeting highlights

enthalten in: Canadian Urological Association journal = Journal de l'Association des urologues du Canada | 2024

von Chi, K. | Canil, C. | Alimohamed, N. | +2

5

Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma

enthalten in: Oral oncology | 2024

von Hes, C. | Desilets, A. | Tonneau, M. | +19

6

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

enthalten in: European urology oncology | 2023

von Sawaya, G. | Dragomir, A. | Wood, L. | +17

7

Predictors of prolonged treatment time intervals in oral cavity cancer

enthalten in: Oral oncology | 2023

von Dayan, G. | Bahig, H. | Fortin, B. | +14

8

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)

enthalten in: European urology | 2023

von Plimack, E. | Powles, T. | Stus, V. | +18

ErratumFor: Eur Urol. 2023 Nov;84(5):449-454. - PMID 37500340

9

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

enthalten in: European urology | 2023

von Plimack, E. | Powles, T. | Stus, V. | +18

ErratumIn: Eur Urol. 2023 Sep 2;:. - PMID 37666734

10

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

enthalten in: JCO global oncology | 2023

von Cardenas, L. | Ghosh, S. | Finelli, A. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[27]